Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
28.63
+1.20 (4.37%)
At close: Aug 13, 2025, 4:00 PM
28.55
-0.08 (-0.28%)
After-hours: Aug 13, 2025, 4:21 PM EDT
Alkermes Revenue
Alkermes had revenue of $390.66M in the quarter ending June 30, 2025, a decrease of -2.12%. This brings the company's revenue in the last twelve months to $1.51B, down -0.17% year-over-year. In the year 2024, Alkermes had annual revenue of $1.56B, down -6.36%.
Revenue (ttm)
$1.51B
Revenue Growth
-0.17%
P/S Ratio
3.11
Revenue / Employee
$836,276
Employees
1,800
Market Cap
4.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.56B | -105.77M | -6.36% |
Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
Dec 31, 2022 | 1.11B | -61.96M | -5.28% |
Dec 31, 2021 | 1.17B | 135.00M | 13.00% |
Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ALKS News
- 14 days ago - Alkermes: A More Than Solid Quarter - Seeking Alpha
- 15 days ago - Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Alkermes plc Reports Second Quarter 2025 Financial Results - PRNewsWire
- 23 days ago - Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PRNewsWire
- 4 weeks ago - Alkermes to Report Second Quarter Financial Results on July 29, 2025 - PRNewsWire
- 2 months ago - Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - PRNewsWire
- 2 months ago - Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences - PRNewsWire
- 3 months ago - Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible - Seeking Alpha